Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025

Reuters

2025/07/22

<a href="https://laohu8.com/S/RPGLF">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025

Regent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553023543"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553023543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553023543?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553023543","market":"us","top_or_hot":-1,"title":"Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RPGLF\">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/00575\">Regent Pacific</a> Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-22 17:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RPGLF\">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/00575\">Regent Pacific</a> Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00575","symbol_name":"勵晶太平洋","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL9GsK51:1","article_id":"2553023543","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553023543","pubTimestamp":1753174808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Regent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin/Senstend, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application  with China's National Medical Products Administration . The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00575":"励晶太平洋"},"translate_title":"Regent Pacific Group Ltd.宣布Senstend NDA审查取得进展™在中国，预计2025年底获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00575":0.9},"content_text":"Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    \n\nRegent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}